Last update March 9, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
M01AH04 is Parecoxib Sodium in ATC Code/s.Is written in other languages:
M01AH04 belongs to this group or family:
Main tradenames from several countries containing M01AH04 in its composition:
|Tmax||0.5 - 1||hours|
|T½||0.3 (Pare); 8 (Valde)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Non-steroidal anti-inflammatory drug (NSAID) that functions as a selective inhibitor of the cyclooxygenase-2 (COX-2) enzyme. It is a prodrug that is metabolized into valdecoxib, which was withdrawn from the market on 2005 due to cardiovascular toxicity after chronic use.
Prescribed for the limited and short-term treatment of postoperative pain.
Intravenous or intramuscular administration given every 6 to 12 hours and for a maximum of three days.
Its pharmacokinetic data (wide volume of distribution and high percentage of protein binding) explain the observed null or negligible passage to milk, that is not clinically significant (Paech 2012, EMA 2012).
No problems have been reported in infants of mothers given a single dose (Paech 2012).
A limited and short-term treatment administered at a minimum therapeutic dose can be regarded as compatible with breastfeeding.